1. Introduction {#sec1}
===============

Pain is common among patients with head and neck cancer (HNC) prior to treatment and may be attributed to the cancer and/or cancer treatment. Pain in HNC patients could be due to tissue damage from several mechanisms such as mucosal injury, nerve compression, and invasion of the tumor into adjacent tissue structures with inflammation or ischemia \[[@B1]\]. Management of HNC includes stage-dependent single or multimodality approaches comprising surgery, chemotherapy, and/or radiation therapy (XRT). Postoperative pain can be due to tissue injury with muscle spasm and nerve injury leading to a combination of inflammatory and neuropathic components \[[@B2]\]. Chemotherapy-induced peripheral neuropathic pain is common and can be due to a combination of mitochondrial dysfunction, changes in expression of various cytokines, and abnormal spontaneous discharge in A and C fibers \[[@B3]\]. XRT can induce oral mucositis in patients with HNC and can cause oral pain due to impaired wound healing \[[@B4]\]. Thus, all of these modalities of treatment can cause acute pain, which often resolves within the critical three-month time span after treatment.

HNC can take up to 3 months to disappear histologically after completion of treatment, thus indicating remission of disease \[[@B5]\]. The follow-up visit at 3 months of completion of cancer therapy is particularly important since it helps in establishing the baseline result of treatment response and also marks the timing of the posttreatment baseline imaging \[[@B6], [@B7]\]. A negative PET-CT scan after treatment with chemoradiotherapy in HNC is associated with a high negative predictive value (\>95%), and a negative scan around 3 months after completion of cancer therapy may indicate no residual disease \[[@B5], [@B8]\]. Patients who achieve a complete remission at the three-month posttreatment time point and who are still experiencing pain are thought to be having chronic pain. According to the International Association for the Study of Pain (IASP), "chronic pain" is defined as "the pain that has persisted beyond normal tissue healing time," lasting for "more than 3 months" in the absence of other criteria \[[@B9]\].

Oral mucositis is a common cause of acute pain in HNC patients, and it typically lasts for 2--4 weeks after the end of radiation therapy (XRT) \[[@B10]\]. However, HNC patients can experience pain even up to 6--12 months after the radiation therapy \[[@B11]\]. There are very limited data on the prevalence and characteristics of chronic pain among HNC patients treated with XRT, and it is not clear which subgroup of HNC patients is more prone for chronic pain after XRT. In this retrospective observational study, we investigated the prevalence of chronic pain and the characteristics of patients in complete remission afflicted with chronic posttreatment pain.

2. Methods {#sec2}
==========

2.1. Design {#sec2.1}
-----------

This retrospective study was conducted at Southern Illinois University (SIU) School of Medicine and Memorial Medical Center, Springfield, IL. All head and neck cancer patients aged 18 years and above, treated with radiotherapy from February 2011 to February 2016, were included in the study. Head and neck cancer patients treated only with chemotherapy were excluded. The chart review identified a total of 53 patients, who met the inclusion criteria. Demographic features such as age at diagnosis, gender and race, clinicopathologic features (location, histology, and staging of the cancer), cancer therapy (surgery and chemotherapy) and details pertinent to XRT (such as dose, duration, and area involved) were collected. In terms of location, data pertaining to upper aerodigestive tract sites (oral cavity, pharynx, larynx, nasal cavity, and paranasal sinuses) as well as salivary glands were collected. We focused on cancers of the oral cavity, pharynx, and larynx in this study because of their similarities in epidemiology, treatment, and prognosis; cancers of the lip, salivary gland, nose, paranasal sinuses, middle ear, nerves and bones, thyroid, nonmelanoma skin cancers, lymphoma, and sarcomas were excluded.

Data were also collected regarding the characteristics of pain: location, onset, frequency, severity, nature of pain, and information regarding use of medications including opioids, gabapentin, TCAs, and NSAIDs. Data regarding characteristics of pain up to 3 months after completion of XRT were categorized as "data related to acute pain," and subsequent data (after 3 months of completion of XRT) were considered as "data related to chronic pain." Pain was documented as mild, moderate, or severe based on the documentation in the charts. If pain severity was documented numerically, it was converted into mild (documented as 1--3 in the charts), moderate \[[@B4]--[@B6]\], and severe \[[@B7]--[@B10]\]. The local institutional review board approved the study, protocol number 17-021 (approval date 02/20/2017).

2.2. Statistical Analyses {#sec2.2}
-------------------------

Data were analyzed with the use of SAS software, version 9.4, and Zotero bibliography software was used for citing references. Descriptive statistics were computed for all study variables. Continuous variables are described with measures of central tendency (mean and median) and dispersion (range and standard deviation). Categorical variables are summarized as frequencies and percentages. Given smaller cell sizes, the following adaptations were made during statistical analyses: cancer stages were grouped into "stage 1 or 2" and "stage 3 or 4"; data for mild, moderate, and severe pain were combined into one group, and number of sites of pain were grouped into three categories such as "pain at 0 site," "pain at 1 site," and "pain at 2 + sites." Statistical analysis was not performed for use of TCA\'s given smaller sample size. Fisher\'s exact tests were used to compare categorical variables. Independent *t*-tests (or nonparametric equivalent) were used to compare continuous variables. All significance was assumed at the *p* \< 0.05 level.

3. Results {#sec3}
==========

Demographic and clinicopathologic factors are described in Tables [1](#tab1){ref-type="table"} (categorical variables) and [2](#tab2){ref-type="table"} (continuous variables). Mean age at diagnosis was 61.23 years, and 73.6% were males. 88.7% of the patients had squamous cell carcinoma (*n* = 47), and other types of histology included adenocarcinoma (*n* = 1), high-grade neuroendocrine tumor (*n* = 1), solitary extramedullary plasmacytoma (*n* = 1), and adenoid cystic carcinoma (*n* = 1).

A total of 41 patients (77.4%) reported any kind of treatment for chronic pain, whereas only 32 patients (60.38%) reported any kind of chronic pain, suggesting poor documentation of pain characteristics in the charts. There was insufficient description of nature of pain; among the patients who reported any kind of chronic pain (*n* = 32), only 4 individuals described the nature of their pain (all of them used descriptors of neuropathic pain such as stinging or burning pain) and less than 4 individuals reported onset, frequency of chronic pain, and exacerbating features. Eleven patients died during the study period with average duration of survival of 15 months.

Pharynx ([Table 3](#tab3){ref-type="table"}) was the most common location of cancer (39.6%), and oropharynx was the most frequent subsite of HNC (34%). Site of cancer was associated with use of medications. Specifically, laryngeal cancer (*p*=0.01; supraglottic cancer, *p*=0.021) was associated with higher use of gabapentin, and cancer of pharynx (*p*=0.016; cancer of oropharynx, *p*=0.04) was associated with lower use of gabapentin.

Pharynx (26.4%) was the commonest site of cancer-related chronic pain, followed by oral cavity (24.5%) ([Table 4](#tab4){ref-type="table"}). Chronic neck pain was associated with use of gabapentin (*p*=0.013).

There was a significant association between chronic pain and number of pain sites (*p* \< 0.0001), and chronic pain was also associated with use of opioids (*p*=0.006) ([Table 5](#tab5){ref-type="table"}). There was no significant association between site of cancer and site of cancer-related chronic pain. Surgery was not associated with chronic pain or use of pain medications (details of statistical analyses for surgery, chemotherapy, XRT dose, and duration have been listed as separate tables, which can be found in Tables [6](#tab6){ref-type="table"}[](#tab7){ref-type="table"}[](#tab8){ref-type="table"}--[9](#tab9){ref-type="table"}, respectively). Similarly, chemotherapy had no effect on chronic pain or use of analgesics. XRT dose had no effect on chronic pain or use of pain medications. Likewise, XRT duration was not associated with chronic pain or use of analgesics.

4. Discussion {#sec4}
=============

Pain is common among HNC patients and can be nociceptive, inflammatory, or neuropathic in nature. Nociceptive pain refers to the response to noxious stimuli and continues in the maintained presence of noxious stimuli \[[@B12]\]. Although inflammatory pain typically improves with resolution of inflammation, there is growing evidence to support that in some cases inflammatory state may resolve but a component of pain persists \[[@B13]\]. In an animal model, Christianson et al. showed that chronic inflammatory states may mimic neuropathic-like pain and continue to have persistent allodynia despite resolution of inflammation, and such allodynia responded only to gabapentin \[[@B14]\]. Pathophysiological changes in the pain pathways resulting from repetitive nociceptive stimulation lead to peripheral or central sensitization, which ultimately leads to transition of acute pain into chronic pain in susceptible individuals \[[@B15]\].

Pain is common among patients with HNC; acute post-XRT pain typically lasts for less than 3 months whereas chronic pain lasts for more than 3 months. Based on our clinical experience in managing post-XRT patients with HNC, we observed that chronic pain is commonly encountered; however, there are very limited data in the literature on the characteristics of chronic pain among HNC patients treated with XRT. Kuo and Williams listed 14 studies investigating pain in HNC patients, in which 3 studies reported persistence of pain up to 6--24 months, and prevalence of pain varied from 15% to 46% \[[@B16]\]. Only one study focused on post-XRT pain in HNC patients \[[@B11]\]. Recently, Srivastava et al. reported 54.7% patients reporting chronic post-XRT pain \[[@B17]\]. In our study, the sample size is larger, and we found almost two-thirds of patients to have some characteristics of chronic pain. The higher rate of prevalence of chronic pain in our study could be due to methodological differences as we included any documentation pertaining to chronic pain (location, nature, frequency of pain, etc.) in the study analysis.

We found discrepancy between frequency of treatment and frequency of chronic pain suggesting poor documentation of pain in the medical records, and less than 4 individuals reported onset (*n* = 1), frequency (*n* = 3), and exacerbating factors (*n* = 2) of chronic pain. It is difficult to generalize these data, given small proportion of patients receiving appropriate documentation. Nevertheless, this phenomenon of inadequate pain documentation is not limited to patients with HNC. Fink \[[@B18]\] reported poor documentation of acute and chronic noncancer pain. However, appropriate cancer pain documentation is one of the key elements of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI), and Ranpura et al. showed improvement in documentation of pain among cancer patients with orientation and education of healthcare providers \[[@B19]\].

Mean age at diagnosis in our group was 61.23 years \[[@B20]\], and almost three-fourths of the patients were males (*n* = 39), which is comparable to other studies in the literature \[[@B21]\]. However, we found that most of our patients were Caucasians (*n* = 46, 86.8%) although historically, HNC is more common in African American individuals; this statistic probably reflects local demographics of Central Illinois. According to a population survey in 2013 \[[@B22]\], average Caucasian population in this area is 90.45%. Also, HPV-positive cases of HNC are more common in Caucasians, and we did not assess for HPV status in our study.

Among 53 patients in our study, pharynx was the most common site (39.6%), followed by larynx (32.1%), and among subsites of larynx, supraglottic carcinoma (17%) was the most common site that is consistent with the previous literature \[[@B23], [@B24]\]. In our study, laryngeal cancer (supraglottic cancer in particular) was associated with higher use of gabapentin. Supraglottic cancers usually have worse prognosis, given high frequency of cervical lymph node involvement, recurrences, and visceral metastases, likely explaining the increased use of analgesics.

Site of chronic pain was also associated with use of medications; chronic neck pain was associated with higher use of gabapentin. HNC patients treated with XRT are found to have neuropathic pain \[[@B25]\], and gabapentin is well established to be effective in treating neuropathic pain and seems to be promising in reducing the need for higher doses of opioids \[[@B26]\]. Gabapentin and opioids are commonly prescribed for pain, the likelihood of coprescription is high, and gabapentin appears to potentiate the effect of opioids \[[@B27]\].

There was a significant association between chronic pain and number of pain sites, and individuals with chronic pain were more likely to be treated with opioids. Murphy et al. found increased pain in HNC population to be associated with increased use of opioids \[[@B28]\]. Epstein et al. showed HNC patients treated with XRT to have both nociceptive and neuropathic pain despite ongoing pain management during XRT \[[@B25]\]. Chronic pain has been attributed to radiation therapy among patients with other cancers such as cervical cancer and breast cancer \[[@B29]--[@B31]\]. Several explanations are possible, explaining the chronic nature of pain among HNC patients treated with XRT. It could be related to chronic neuropathic pain or secondary to radiation-induced fibrosis as well as due to effects of XRT on the lymphatic system. Peuckmann et al. found almost half of the patients with chronic in pain breast cancer patients to have paresthesia of the skin corresponding to the areas of surgery and XRT \[[@B31]\]. Allodynia was associated with XRT only. Another mechanism could be that the irradiated tissue developing increased vascular permeability which in turn leads to fibrin deposition, subsequent collagen formation, and fibrosis. Such radiation-induced fibrosis could damage peripheral nerves which could lead to chronic neuropathic pain \[[@B32]--[@B34]\]. Thus, it is possible that such neuropathic pain secondary to XRT might be contributing to chronic pain among HNC patients treated with XRT. XRT could cause somatic pain related to osteonecrosis of bone, and it could also disrupt lymphatics, causing lymphedema and chronic swelling and likely inflammatory pain \[[@B35]\]. However, further research is needed in this field with prospective studies evaluating nature of chronic pain and risk factors among HNC patients treated with XRT.

Higher doses of XRT are known to have a positive correlation with chronic pain among HNC patients, possibly related to radiation-induced fibroatrophic processes \[[@B36]\]. However, we did not find any significant association of XRT dose or XRT duration with chronic pain or with use of pain medications (Tables [8](#tab8){ref-type="table"} and [9](#tab9){ref-type="table"}). This could be due to the lower than average XRT dose used in our study. The average XRT dose in our study was 6063.34 cGy, which is lower as compared to the standard regimen of 7000 cGy. The lower dose may be due to refusal of further XRT by patients due to side effects of treatment and overall poor quality of life.

In our study group, surgery was not associated with chronic pain or use of pain medications ([Table 6](#tab6){ref-type="table"}). Similarly, chemotherapy had no effect on chronic pain or use of analgesics ([Table 7](#tab7){ref-type="table"}). There was no difference in rates of survival among patients with chronic pain as compared to those without pain. We did not have any data on use of botulinum toxin injection in HNC patients. Type-A botulinum toxin is an analgesic and a muscle relaxant and has been used to treat pain related to neck muscle spasm and contracture in post-XRT HNC patients. Along with conventional analgesics, future studies should explore Botulinum toxin injection and other therapies as therapeutic options to treat chronic pain in post-XRT HNC patients \[[@B37], [@B38]\].

Limitations of our study include the fact that it is a retrospective single center study. Comorbid chronic medical conditions were also not adjusted during the statistical analysis. The overall sample size in our study is small, and particularly, very small cell sizes (*n* \< 8) should be interpreted with caution.

5. Conclusions {#sec5}
==============

In summary, post-XRT pain among HNC patients is common not only during the acute period but also in the chronic period lasting well beyond three months after completion of XRT. We found discrepancy between frequency of treatment and frequency of chronic pain, suggesting poor documentation of pain in the medical records. Among patients who reported having chronic post-XRT pain, most of them described having severe pain and used descriptors of neuropathic pain. Pharynx was the commonest site of cancer as well as the commonest site of cancer-related chronic pain; squamous cell carcinoma was the most frequent histological pattern, and opioids were used most often to treat such chronic pain. There was a significant association between chronic pain and number of pain sites, and chronic pain was associated with use of opioids. Surgery was not associated with chronic pain or use of pain medications. Similarly, chemotherapy had no effect on chronic pain or use of analgesics. XRT dose had no effect on chronic pain or use of pain medications. Likewise, XRT duration was not associated with chronic pain or use of pain medications. There was no difference in rates of survival among patients with chronic pain as compared to those without pain. Site of cancer and site of cancer-related chronic pain were associated with use of pain medications. However, these results have to be carefully interpreted, given small sample size. Further research using prospective studies with larger samples is needed to explore the characteristics of chronic pain among HNC patients treated with XRT and parse the roles of chemotherapy and radiation.
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###### 

Demographic and clinicopathologic factors (categorical variables) (frequency and percentage of demographic factors including age, gender, and race and clinicopathologic factors such as histology, cancer staging, severity of pain, and cancer treatment).

  Variable                       *n*        \%     
  ------------------------------ ---------- ------ ------
  *Categorical variables*                          
  Gender                         Female     14     26.4
  Male                           39         73.6   
                                                   
  Race                           White      46     86.8
  AA                             5          9.4    
                                                   
  Histology                      Squamous   47     88.7
                                                   
  Staging                        1          4      7.6
  2                              4          7.6    
  3                              5          9.4    
  4                              21         39.6   
                                                   
  Surgery                        No         32     60.4
  Yes                            21         39.6   
                                                   
  Chemo                          No         21     39.6
  Yes                            32         60.4   
                                                   
  Severity of chronic pain       No pain    35     66.0
  Mild                           1          1.9    
  Moderate                       4          7.5    
  Severe                         13         24.5   
                                                   
  *Medication*                                     
  Use of opioids                 No         20     37.7
  Yes                            33         62.3   
                                                   
  Use of gabapentin              No         45     84.9
  Yes                            8          15.1   
                                                   
  Use of TCAs for chronic pain   No         47     88.7
  Yes                            6          11.3   
                                                   
  Use of NSAIDs                  No         39     73.6
  Yes                            14         26.4   

###### 

Demographic and clinicopathologic factors (continuous variables).

  Variable                  *n*     Mean      Std. error   Median    Std. dev.   Min.     Max.
  ------------------------- ------- --------- ------------ --------- ----------- -------- ---------
  Age at diagnosis          53      61.23     1.73         59.00     12.62       40.00    91.00
  XRT dose                  53      6063.34   201.30       6600.00   1465.47     600.00   7000.00
  XRT duration              53      43.04     1.77         45.00     12.85       4.00     75.00
  Number of sites of pain   53.00   1.21      0.19         1.00      1.38        0.00     6.00

###### 

Site of cancer: frequency and percentage of prevalence of cancer by site and subsites and association between site of cancer and use of medications^*∗*^.

  Site of cancer                           Total   Use of opioids   Use of NSAIDs   Use of gabapentin                                 
  ---------------------------------------- ------- ---------------- --------------- ------------------- ------- ------ ------- ------ -----------
  **1. Oral cavity**                       No      47               88.7            61.7                1       25.5   0.649   12.8   0.219
  Yes                                      6       11.3             66.7            33.3                33.3                          
                                                                                                                                      
  1A. Lip                                  No      53               100             62.3                ---     26.4   ---     15.1   ---
  Yes                                      0       0                                                                                  
                                                                                                                                      
  1B. Buccal mucosa                        No      53               100             62.3                ---     26.4   ---     15.1   ---
  Yes                                      0       0                                                                                  
                                                                                                                                      
  1C. Alveolar ridge, retromolar trigone   No      50               94.3            62.0                1       24.0   0.167   16.0   1
  Yes                                      3       5.7              66.7            66.7                0.0                           
                                                                                                                                      
  1D. Floor of mouth                       No      50               94.3            60.0                0.282   26.0   1       12.0   0.056
  Yes                                      3       5.7              100.0           33.3                66.7                          
                                                                                                                                      
  1E. Hard palate                          No      52               98.1            63.5                0.377   26.9   1       15.4   1
  Yes                                      1       1.9              0.0             0.0                 0.0                           
                                                                                                                                      
  1F. Oral tongue                          No      51               96.2            60.8                0.521   25.5   0.462   15.7   1
  Yes                                      2       3.8              100.0           50.0                0.0                           
                                                                                                                                      
  **2. Pharynx**                           No      32               60.4            62.5                1       31.3   0.362   25.0   **0.016**
  Yes                                      21      39.6             61.9            19.0                0.0                           
                                                                                                                                      
  2A. Nasopharynx                          No      52               98.1            63.5                0.377   26.9   1       15.4   1
  Yes                                      1       1.9              0.0             0.0                 0.0                           
                                                                                                                                      
  **2B. Oropharynx**                       No      35               66              60.0                0.768   25.7   1       22.9   **0.04**
  Yes                                      18      34               66.7            27.8                0.0                           
                                                                                                                                      
  **2C. Oropharynx: base of tongue**       No      44               83              63.6                0.715   27.3   1       18.2   0.324
  Yes                                      9       17               55.6            22.2                0.0                           
                                                                                                                                      
  2D. Soft palate                          No      49               92.5            63.3                0.627   28.6   0.563   16.3   1
  Yes                                      4       7.5              50.0            0.0                 0.0                           
                                                                                                                                      
  **2E. Tonsillar fossa pillar**           No      43               81.1            58.1                0.286   25.6   1       18.6   0.327
  Yes                                      10      18.9             80.0            30.0                0.0                           
                                                                                                                                      
  **2F. Hypopharynx, pyriform sinus**      No      46               86.8            65.2                0.405   30.4   0.17    17.4   0.577
  Yes                                      7       13.2             42.9            0.0                 0.0                           
                                                                                                                                      
  **3. Larynx**                            No      36               67.9            55.6                0.225   19.4   0.109   5.6    **0.01**
  Yes                                      17      32.1             76.5            41.2                35.3                          
                                                                                                                                      
  **3A. Supraglottis**                     No      44               83              56.8                0.129   27.3   1       9.1    **0.021**
  Yes                                      9       17               88.9            22.2                44.4                          
                                                                                                                                      
  **3B. Glottis**                          No      46               86.8            60.9                0.697   21.7   0.07    13.0   0.283
  Yes                                      7       13.2             71.4            57.1                28.6                          
                                                                                                                                      
  3C. Subglottis                           No      50               94.3            60.0                0.282   26.0   1       14.0   0.394
  Yes                                      3       5.7              100.0           33.3                33.3                          
                                                                                                                                      
  4\. Nasal cavity                         No      50               94.3            62.0                1       28.0   0.557   16.0   1
  Yes                                      3       5.7              66.7            0.0                 0.0                           
                                                                                                                                      
  5\. Paranasal sinuses                    No      53               100             62.3                ---     26.4   ---     15.1   ---
  Yes                                      0       0                                                                                  
                                                                                                                                      
  6\. Others                               No      50               94.3            64.0                0.549   28.0   0.557   16.0   1
  Yes                                      3       5.7              33.3            0.0                 0.0                           
                                                                                                                                      
  7\. Salivary gland                       No      50               94.3            66.0                0.049   26.0   1       16.0   1
  Yes                                      3       5.7              0.0             33.3                0.0                           

^*∗*^Several cell sizes are very small and have been excluded from final statistical analyses. The ones that are included in the interpretation of final results are described in bold text.

###### 

Various sites of pain among HNC patients and association between site of pain and use of medications^*∗*^.

  Site of pain                          Total   Use of opioids   Use of NSAIDs   Use of gabapentin                                 
  ------------------------------------- ------- ---------------- --------------- ------------------- ------- ------ ------- ------ -----------
  **1. Oral cavity**                    No      40               75.5            55.0                0.098   27.5   1       15.0   1
  Yes                                   13      24.5             84.6            23.1                15.4                          
                                                                                                                                   
  **2. Pharynx**                        No      39               73.6            56.4                0.203   28.2   0.735   17.9   0.665
  Yes                                   14      26.4             78.6            21.4                7.1                           
                                                                                                                                   
  3\. Eyes                              No      52               98.1            61.5                1       26.9   1       15.4   1
  Yes                                   1       1.9              100.0           0.0                 0.0                           
                                                                                                                                   
  4\. Nasal cavity, paranasal sinuses   No      52               98.1            61.5                1       26.9   1       15.4   1
  Yes                                   1       1.9              100.0           0.0                 0.0                           
                                                                                                                                   
  **5. Odynophagia**                    No      44               83              59.1                0.456   25.0   0.684   13.6   0.611
  Yes                                   9       17               77.8            33.3                22.2                          
                                                                                                                                   
  6\. Headache                          No      50               94.3            60.0                0.282   24.0   0.167   14.0   0.394
  Yes                                   3       5.7              100.0           66.7                33.3                          
                                                                                                                                   
  **7. Face**                           No      48               90.6            58.3                0.144   27.1   1       14.6   0.574
  Yes                                   5       9.4              100.0           20.0                20.0                          
                                                                                                                                   
  **8. Ear**                            No      45               84.9            57.8                0.234   24.4   0.422   13.3   0.59
  Yes                                   8       15.1             87.5            37.5                25.0                          
                                                                                                                                   
  **9. Neck**                           No      45               84.9            60.0                0.695   22.2   0.186   8.9    **0.013**
  Yes                                   8       15.1             75.0            50.0                50.0                          

^*∗*^Several cell sizes are very small and have been excluded from final statistical analyses. The ones that are included in the interpretation of final results are described in bold text.

###### 

Characteristics of chronic pain.

                            Chronic pain   Fisher\'s                                                
  ------------------------- -------------- ----------- -------- ----------- ------------ ---------- --------------
  Gender                    Female         10          4        14          71.4         28.6       0.748
  Male                      25             14          39       64.1        35.9                    
                                                                                                    
  Staging                   Stage 1 or 2   4           4        8           50.0         50.0       0.679
  Stage 3 or 4              17             9           26       65.4        34.6                    
                                                                                                    
  Surgery                   No             22          10       32          68.8         31.3       0.768
  Yes                       13             8           24       54.2        33.3                    
                                                                                                    
  Chemo                     No             16          5        21          76.2         23.8       0.247
  Yes                       19             13          32       59.4        40.6                    
                                                                                                    
  Opioids                   No             18          2        20          90.0         10.0       **0.006**
  Yes                       17             16          33       51.5        48.5                    
                                                                                                    
  Gabapentin                No             33          12       45          73.3         26.7       0.014
  Yes                       2              6           8        25.0        75.0                    
                                                                                                    
  TCA                       No             32          15       47          68.1         31.9       0.397
  Yes                       3              3           6        50.0        50.0                    
                                                                                                    
  NSAID                     No             28          11       39          71.8         28.2       0.191
  Yes                       7              7           14       50.0        50.0                    
                                                                                                    
  Number of sites of pain   0              20          1        21          95.2         4.8        **\<0.0001**
  1                         11             4           15       73.3        26.7                    
  2+                        4              13          17       23.5        76.5                    
                                                                                                    
  Variable                  Chronic pain   N           Mean     Std. dev.   Std. error   *t*-test    
  Age                       Pain = no      35          62.23    13.831      2.338        0.425       
  Pain = yes                18             59.28       9.916    2.337                               
                                                                                                    
  Dose                      Pain = no      35          5854     1562.68     264.14       0.149       
  Pain = yes                18             6470        1191.5   280.84                              
                                                                                                    
  Duration                  Pain = no      35          42.37    14.534      2.457        0.604       
  Pain = yes                18             44.33       8.957    2.111                               

###### 

Surgery and medications.

  Surgery   No                    Yes   Total   Fisher\'s *p* value
  --------- --------------------- ----- ------- ---------------------
            *Use of opioids*                    
  No        14                    18    32      0.3859
  Yes       6                     15    21      
                                                
            *Use of gabapentin*                 
  No        29                    3     32      0.2403
  Yes       16                    5     21      
                                                
            *Use of TCA*                        
  No        28                    4     32      1
  Yes       19                    2     21      
                                                
            *Use of NSAIDs*                     
  No        23                    9     32      1
  Yes       16                    5     21      

###### 

Chemotherapy and medications.

  Chemo   No                    Yes   Total   Fisher\'s *p* value
  ------- --------------------- ----- ------- ---------------------
          *Use of opioids*                    
  No      9                     12    21      0.5733
  Yes     11                    21    32      
                                              
          *Use of gabapentin*                 
  No      16                    5     21      0.2403
  Yes     29                    3     32      
                                              
          *Use of TCA*                        
  No      18                    3     21      0.6711
  Yes     29                    3     32      
                                              
          *Use of NSAIDs*                     
  No      13                    8     21      0.2017
  Yes     26                    6     32      

###### 

XRT dose and medications.

               *n*   Mean      Std. dev.   Std. error   *p* value   Test    
  ------------ ----- --------- ----------- ------------ ----------- ------- ---------------
  Opioids      No    20        5398.00     1910.38      427.17      0.05    Mann--Whitney
  Yes          33    6466.58   937.33      163.17                           
                                                                            
  Gabapentin   No    45        5981.80     1561.94      232.84      0.342   *t*-test
  Yes          8     6522.00   579.23      204.79                           
                                                                            
  TCA          No    47        6101.21     1422.24      207.45      0.603   *t*-test
  Yes          6     5766.67   1899.12     775.31                           
                                                                            
  NSAID        No    39        5922.69     1618.93      259.24      0.247   *t*-test
  Yes          14    6455.14   839.43      224.35                           

###### 

XRT duration and medications.

               *n*   Mean    Std. dev.   Std. error   *p* value   Test    
  ------------ ----- ------- ----------- ------------ ----------- ------- ---------------
  Opioids      No    20      38.20       16.13        3.61        0.277   Mann--Whitney
  Yes          33    45.97   9.51        1.66                             
                                                                          
  Gabapentin   No    45      41.89       13.36        1.99        0.124   *t*-test
  Yes          8     49.50   6.97        2.46                             
                                                                          
  TCA          No    47      42.81       11.92        1.74        0.72    *t*-test
  Yes          6     44.83   20.19       8.24                             
                                                                          
  NSAID        No    39      42.56       13.42        2.15        0.659   *t*-test
  Yes          14    44.36   11.47       3.07                             

[^1]: Academic Editor: Federica Galli
